Po-Shun Lee

Nessuna posizione attualmente

54 anni

Health Technology

Consumer Services

Profilo

Po-Shun Lee is the founder of Critical Biologics Corp.
which was founded in 2006.
He worked as an Associate Medical Director at Vertex Pharmaceuticals, Inc. from 2010 to 2013.
From 2014 to 2019, he worked as the Chief Medical Officer & Executive Vice President at Proteostasis Therapeutics, Inc. Dr. Lee holds a doctorate degree from the University of Pennsylvania and an undergraduate degree from The Johns Hopkins University.

Precedenti posizioni note di Po-Shun Lee

Società	Posizione	Fine
PROTEOSTASIS THERAPEUTICS, INC.	Chief Tech/Sci/R&D Officer	22/07/2019
VERTEX PHARMACEUTICALS INCORPORATED	Corporate Officer/Principal	01/01/2013
Critical Biologics Corp. Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA.	Founder	-

Vedi nel dettaglio l'esperienza di Po-Shun Lee

Formazione di Po-Shun Lee

University of Pennsylvania	Doctorate Degree
The Johns Hopkins University	Undergraduate Degree

Esperienze
Posizioni ricoperte

Attive

Inattive

Società quotate in Borsa

Aziende private

Vedi nel dettaglio l'esperienza di Po-Shun Lee

Relazioni

Relazioni di 1° grado

Aziende connesse in 1º grado

Uomo

Donna

Amministratori

Dirigenti

Vedi i contatti personali

Società collegate

Società quotate in Borsa	1
VERTEX PHARMACEUTICALS INCORPORATED	Health Technology

Aziende private	2
Critical Biologics Corp. Critical Biologics Corp. Medical SpecialtiesHealth Technology Critical Biologics Corp. develops and commercializes diagnostics and therapeutics drugs. The firm focuses in the development of a theranostic platform to screen and treat both acute and chronic patients with low plasma gelsolin levels (hypogelsolinemia) at high risk of life-threatening complications. The company was founded by James W. Fordyce, Terence S. Russell, Shun Lee Po, and Thomas P. Stossel in 2006 and is headquartered in Cambridge, MA.	Health Technology
Proteostasis Therapeutics, Inc. Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA.	Health Technology